Exagen Showcases Six Scientific Presentations at ACR’s First Virtual Annual Meeting in November 2020

Rhea-AI Summary

Exagen Inc. (XGN) announced participation in the ACR Convergence 2020, a virtual meeting scheduled from November 5-9, where its research on autoimmune diseases, specifically lupus, will be presented. Chief Scientific Officer Anja Kammesheidt emphasized their commitment to advancing understanding of cell-bound complement activation products (CB-CAPs). Several abstracts have been accepted for presentation, showcasing innovative testing products under the AVISE® brand. This event is anticipated to enhance awareness and adoption of Exagen's diagnostics.

Positive

• Participation in ACR Convergence 2020 enhances visibility and credibility.
• Presentation of innovative research could lead to increased adoption of AVISE® tests.

Negative

• Dependence on market acceptance of testing products poses a risk to future revenue.

SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today it will be presenting new scientific research at the American College of Rheumatology’s (ACR) first virtual annual meeting, ACR Convergence 2020. The event is being held online from November 5-9, 2020.

Exagen’s Chief Scientific Officer, Anja Kammesheidt, shared, “Exagen is honored to have had the opportunity to partner with such great collaborators on this year’s abstracts. Our clinical research and development teams are committed to advancing the understanding of the role of cell-bound complement activation products (CB-CAPs) in lupus. We are pleased to be sharing these data at this year’s virtual ACR event.”

Below is the list of accepted abstracts along with links to each:

Saturday, November 7th

Poster Presentation | Presented by Michelle Petri, MD | Abstract #0857
Title: Agreement of Hydroxychloroquine Blood Levels Between a University and Commercial Laboratory
Session Title: SLE – Treatment Poster I
Session Time: 9:00 am – 11:00 am EST

Sunday, November 8th

Oral Presentation | Presented by Yevgeniya Gartshteyn, MD | Abstract #1510
Title: Platelet-bound C4d is Associated with Platelet Activation and Arterial Thrombotic Events
Session Title: SLE – Diagnosis, Manifestations, & Outcomes II: Bench to Bedside (1507–1511)
Session Time: 3:00 pm – 3:50 pm EST

Oral Presentation | Presented by Michelle Petri, MD | Abstract #1513
Title: Role of Platelet C4d in Thrombosis and Lupus Nephritis
Session Title: SLE – Diagnosis, Manifestations, & Outcomes III: Lupus Nephritis (1512–1516)
Session Time: 4:00 pm – 4:50 pm EST

Monday, November 9th

Poster Presentation | Presented by Yevgeniya Gartshteyn, MD | Abstract #1792
Title: Platelet-bound C4d is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE
Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside
Session Time: 9:00 am – 11:00 am EST

Poster Presentation | Presented by Rosalind Ramsey-Goldman, MD | Abstract #1797
Title: A Multianalyte Assay Panel (MAP) With Algorithm Containing Cell-Bound Complement Activation Products (CB-CAPs) Is Superior to Anti-dsDNA And Low Serum Complement Levels in Predicting Transition of Probable Lupus to ACR Classified Lupus Within 2 Years
Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside
Session Time: 9:00 am – 11:00 am EST

Poster Presentation | Presented by Jill Buyon, MD | Abstract #1808
Title: Erythrocyte Complement Receptor 1 (ECR1) and Erythrocyte Bound C4d (EC4d) Associate with Adverse Pregnancy Outcomes and Preeclampsia in Pregnant Women with Systemic Lupus Erythematosus (SLE)
Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside
Session Time: 9:00 am – 11:00 am EST

* Abstracts will remain live until March 11, 2021

About Exagen Inc.

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand. Several of these products are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway implicated in systemic lupus erythematosus, or SLE. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Exagen’s model of integrating testing products and therapeutics positions Exagen to offer targeted solutions to rheumatologists and, ultimately, better serve patients.  For more information, please visit www.Exagen.com 

Forward Looking Statements

Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the scientific abstracts for presentation at ACR Annual Conference and the potential to lead to increased adoption of any AVISE® test.  The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: the COVID-19 pandemic may continue to adversely affect our business, financial condition and results of operations, Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products and promoted therapeutics among rheumatologists, patients, third-party payers and others in the medical community; third party payers not providing coverage and adequate reimbursement for the company’s testing products or promoted therapeutics; the company’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting the company’s business; risks associated with maintaining third-party partnerships and Exagen’s performance thereunder; and other risks described in the company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the company’s Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investors
Westwicke Partners
Mike Cavanaugh
Mike.Cavanaugh@westwicke.com
646.677.1838

Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
kadawi@exagen.com
760.477.5514

FAQ

What is Exagen presenting at ACR Convergence 2020?

Exagen will present research on the role of cell-bound complement activation products (CB-CAPs) in lupus.

When is the ACR Convergence 2020 event?

The ACR Convergence 2020 will be held online from November 5-9, 2020.

What is the focus of Exagen's research?

Exagen focuses on transforming care for patients with autoimmune diseases, particularly through innovative testing for lupus.

What is the significance of the data shared by Exagen?

The data could enhance the understanding of lupus and potentially increase the adoption of Exagen's AVISE® tests.

How does Exagen's research impact investors?

Investors may see potential growth opportunities if Exagen's research leads to increased market acceptance of its products.